Testosterone Therapy for Women Prescription Denials
Analysis based on 7 articles · First reported Sep 15, 2026 · Last updated Sep 15, 2026
The surge in off-label testosterone use and pharmacy friction could boost demand for compounding pharmacies and create opportunities for companies developing women-specific testosterone products. Regulatory attention from the FDA workshop may lead to clearer guidelines, potentially expanding the market but also increasing scrutiny on off-label prescribing.
Women are increasingly seeking testosterone therapy for menopause symptoms, but face prescription delays and denials at major pharmacies. There is no U.S.-approved testosterone product for women, though off-label use has surged 146% from January 2023 to July 2026 according to a Truveta analysis for Reuters. Canadian Menopause Society and other medical organizations only endorse testosterone for hypoactive sexual desire disorder in menopausal women. The United States — Food and Drug Administration will hold a public workshop on Thursday to review evidence, promoted by Robert F. Kennedy Jr. and Pete Hegseth. Amazon (company) Pharmacy has rejected some prescriptions requiring customized dosing, citing safety and compliance, while CVS Health says it regularly fills topical testosterone gel prescriptions for women. Walgreens Boots Alliance, Costco, Walmart and Kroger did not respond or declined to comment. Compounded testosterone costs about $100 for a three-month supply versus $30 for a 10-month supply at commercial pharmacies, and most insurers do not cover it. Over 30 trials are underway, including one sponsored by Marius Pharmaceuticals, and Aviva Bio is developing a next-generation product. AbbVie, Upsher-Smith Laboratories and Bicara Therapeutics currently supply branded and generic gels.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard